My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Aurinia Pharmaceuticals Inc - Common Shares (NQ:AUPH)

11.49 +0.02 (+0.22%)
Streaming Delayed Price Updated: 3:10 PM EDT, Oct 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Aurinia Pharmaceuticals Inc - Common Shares

< Previous 1 2 3 4 5 6 7 Next >
Aurinia Announces Upcoming Presentations of New Data on LUPKYNIS® at American College of Rheumatology Convergence and American Society of Nephrology Kidney Week 2025
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Responds to Now Retracted LinkedIn Post
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2025
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Pharmaceuticals to Release Second Quarter 2025 Financial and Operational Results on July 31, 2025
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Announces Positive Results from Phase 1 Study of Aritinercept (AUR200)
From Aurinia Pharmaceuticals Inc.
Via Business Wire
New AURORA 1 Analysis: LUPKYNIS-Based Triple Immunosuppressive Therapy Yields Deep Proteinuria Reduction in Lupus Nephritis
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Pharmaceuticals to Host Conference Call to Discuss AUR200 Phase 1 Study Results on June 30, 2025
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2025
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Pharmaceuticals to Release First Quarter 2025 Financial and Operational Results on May 12, 2025
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Glass Lewis Recommends That Aurinia Shareholders Vote “FOR” All Proposals at 2025 Annual General Meeting
From Aurinia Pharmaceuticals Inc.
Via Business Wire
ISS Recommends That Aurinia Shareholders Vote “FOR” All Proposals at 2025 Annual General Meeting
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Pharmaceuticals Reports Financial Results for the Three and Twelve Months Ended December 31, 2024 and Provides Update on Recent Corporate Progress
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Pharmaceuticals to Release 2024 Fourth Quarter and Full Year Financial and Operational Results on February 27, 2025
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Commends 2024 Updated ACR Guidelines for Screening, Treatment, and Management of Lupus Nephritis
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Presents New Data Underscoring Critical Importance of Earlier Lupus Nephritis Detection and Intervention and Value of LUPKYNIS® in Managing LN at American College of Rheumatology Convergence 2024
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia to Participate in Jefferies London Healthcare Conference
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Pharmaceuticals Appoints Craig Johnson to Board of Directors to Support Next Phase of Growth
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2024 Financial and Operational Results, Announces Strategic Restructuring to Sharpen Focus on Continued LUPKYNIS® Growth and AUR200 Development
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Pharmaceuticals to Release Third Quarter Financial and Operational Results on November 7, 2024
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Announces Japan Approval of LUPKYNIS® (Voclosporin) to Treat Lupus Nephritis
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia to Participate in 2024 Cantor Fitzgerald Global Healthcare Conference
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Announces Board Restructuring
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Announces First Participant Dosed in AUR200 Single Ascending Dose Trial
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia to Participate in H.C. Wainwright 26th Annual Global Investment Conference
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Pharmaceuticals Reports Second Quarter and Six Months 2024 Financial and Operational Results
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Pharmaceuticals to Release Second Quarter Financial and Operational Results on August 1, 2024
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia to Participate in Upcoming Investor Healthcare Conferences
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Announces 2024 Annual General Meeting Results
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Presents Safety and Efficacy Profile of LUPKYNIS® for People with Lupus Nephritis at European Alliance of Associations for Rheumatology (EULAR) Congress 2024
From Aurinia Pharmaceuticals Inc.
Via Business Wire
Aurinia Addresses Dubious Proposals Put Forth by Lucien Selce
From Aurinia Pharmaceuticals Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.